
The material cannot be used for any other purpose without further permission of the publisher and is for private use only.

There may be differences between this version and the published version. You are advised to consult the publisher’s version if you wish to cite from it.

This is the peer reviewed version of the following article:

Bekfani, T. et al. (2021) A current and future outlook on upcoming technologies in the remote monitoring of patients with heart failure. European Journal of Heart Failure, 23(1), pp. 175-185, which has been published in final form at: 10.1002/ejhf.2033

This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

https://eprints.gla.ac.uk/225874/

Deposited on: 3 November 2020
A Current and Future Outlook on Upcoming Technologies in the Remote Monitoring of Patients with Heart Failure

Tarek Bekfani¹, Marat Fudim², John G.F. Cleland³, Ana Jorbenadze⁴, Stephan von Haehling⁵, Avraham Lorber⁶, Alexander M-K. Rothman⁷, Kenneth Stein⁸, William T. Abraham⁹, Horst Sievert¹⁰,¹¹, Stefan D. Anker¹²,¹³

¹ Department of Internal Medicine I, Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Magdeburg, Otto von Guericke-University, Magdeburg, Germany
² Duke University Medical Center, Division of Cardiology, Durham, NC, USA
³ Robertson Centre for Biostatistics and Clinical Trials Unit, Institute of Health and Wellbeing, University of Glasgow and National Heart & Lung Institute, Imperial College, London, UK
⁴ Tbilisi Heart and Vascular Clinic, Tbilisi, Georgia
⁵ University of Göttingen Medical Centre, Department of Cardiology and Pneumology, Göttingen, Germany and German Centre for Cardiovascular Research (DZHK), partner site Göttingen, Germany
⁶ Pi-Harvest, Ziv Hospital Safed Israel
⁷ University of Sheffield and Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom
⁸ Boston Scientific, Marlborough, MA, USA
⁹ Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio, USA
¹⁰ CardioVascular Center Frankfurt, Frankfurt, Germany
¹¹ Anglia Ruskin University, Chelmsford, UK
¹² Division of Cardiology and Metabolism – Heart Failure, Cachexia & Sarcopenia, Department of Cardiology, Campus Virchow-Klinikum, Charité – Medical School, Berlin, Germany
¹³ Berlin-Brandenburg Centre for Regenerative Therapies (BCRT), Charité – Medical School Berlin, Berlin, Germany

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/ejhf.2033
Corresponding author:
Dr. Tarek Bekfani
Department of Cardiology
University Hospital Magdeburg
Leipziger Strasse 44
39120 Magdeburg, Germany
Tel.: +49 391 67-13229
Fax: +49 391 67-13202
tarek.bekfani@med.ovgu.de

Total word count of the manuscript: 4207.
ABSTRACT

Heart failure is a major health and economic challenge in both developing and developed countries. Despite advances in pharmacological and device therapies for patients with a reduced left ventricular ejection fraction (LVEF) and heart failure (HFrEF), their quality of life (QoL) and exercise capacity are often persistently impaired, morbidity and mortality remain high and the health economic and societal costs are considerable. For patients with heart failure and preserved LVEF (HFpEF), diuretic management has an essential role for controlling congestion and symptoms even if no intervention has been convincingly shown to reduce morbidity or mortality.

Remote monitoring might improve care delivery and clinical outcomes for patients regardless of LVEF. A great variety of innovative remote monitoring technologies and algorithms are being introduced, including patient self-managed testing, wearable either as integrated into established clinically indicated therapeutic devices, such as pacemakers and defibrillators, or as stand-alone are in development providing the promise of further improvements in service delivery and clinical outcomes. In this article, we will discuss unmet needs in the management of patients with HF, how remote monitoring might contribute to future solutions and provide an overview of current and novel remote monitoring technologies.

Keywords: Heart Failure, Remote monitoring.
INTRODUCTION

Heart failure (HF) is a major health, social and economic problem worldwide (1). Incidence and prevalence are increasing (2), in part due to an aging population and rising burden of comorbidities (3). Efforts to decrease mortality, reduce hospitalization rates and improve the well-being of patients with HF were modestly successful over the last decades in spite of the introduction of many effective medical therapies and care strategies (4). Indeed, HF readmission-rates remain high and represent an increasingly unsustainable financial burden (5). In the U.S. alone, the costs related to HF are expected to reach 70 billion U.S. dollars by 2030, an increase of 130% on current costs (6-8). The 30-day readmission rate as a key indicator of hospital performance is still with currently 25% high (9, 10). As a result, reducing readmission rates has become a priority in many of the developed countries (11, 12).

Adherence to guideline directed medical therapy (GDMT) (13), the provision of an effective care plan to patients with advanced HF and an effective discharge planning performed by a multidisciplinary expert team are all purported to reduce hospitalization rates and health costs (14-16). Unfortunately, data from registries show that only a small proportion of patients with HF achieve optimal doses of recommended HF-therapy (17-20).

Understanding the pathophysiology of HF makes achieving and maintaining an euvoletic status a key goal in the management of HF. As a response to the reduced cardiac output, the human body attempts to maintain an effective mean arterial pressure through a series of compensatory mechanisms. Over-activation of the sympathetic nervous system and renin-angiotensin-aldosterone system are among the earliest pathophysiological responses (21) along with an increased metabolic rate driven by an active inflammatory process. Over the course of days to weeks, the body starts to retain salt and water. Paired with a decreased vascular compliance due to vasoconstriction, patients at this stage retain fluid, increase cardiac filling pressures, increase interstitial pulmonary fluid and lastly increase weight (22).
Accordingly, a modified approach to patients with HF seems to be necessary. Historically clinicians tended to intervene at a later stage in the development of decompensation (phase C or D, Figure 1). However, based on monitoring of physiological variables that change early, meaningful clinical intervention might be necessary at an earlier phase (phase A or B) to control overt decompensation. It is estimated that earliest detectable changes in physiological measurements might occur 10-20 days prior to an onset of symptoms (18).

As such, new means and technologies to improve monitoring of such parameters and care delivery are urgently required. Novel telemedicine technologies (also called remote monitoring-RM) could represent a solution to the above-mentioned unmet needs in patients with HF in a manner similar to current practice in diabetes management through patients’ education to improve adherence to lifestyle and medical therapies and to take a prompt action, when necessary. This should focus in the case of HF on adjusting the doses of diuretics (11, 13). This is of special importance in patients with HFpEF that lack proven pharmacological treatments, and are susceptible to cardiac decompensations and mortality rates comparable to patients with HFrEF (23). Patients with HFpEF were so far underrepresented in many RM trials.

The utility of RM has become more apparent in the current state of a global COVID-19 pandemic, where social distancing is recommended and the number of in-person patient-physician contacts has dramatically declined (24).

Although the need and utility of RM appears intuitive, evidence to support the clinical benefit has been mixed, however. The reasons why some trials failed to show improvements in outcome may be diverse, due variously to patient selection, inadequate statistical power, insufficient sensitivity or specificity of the sensors or algorithms, failure by health professionals or patients to act on the information. In addition, the interpretation of the results of some trials may be unduly pessimistic. For instance, in both BEAT and TELE-HF, the
improvement in quality of life was greater with telemonitoring than observed in either with Sacubitril/Valsartan in PARADIGM or dapagliflozin in DAPA-HF. Also, the absolute difference in mortality in BEAT-HF was larger at 6 months than for either of these much more highly powered pharmaceutical trials. Availability, affordability, accessibility, and appropriateness are ideal characters of devices used in RM.

We will discuss in this review article the existing evidence of RM and its significance to address the unmet needs in HF management. The review reflects discussions among representatives from academia, industry, and regulatory agencies at the Device-Heart Failure meeting (D-HF) (Paris, France, December 2019).

RESULTS FROM RECENT LANDMARK TRIALS

The effectiveness of RM to improve life expectancy, QoL, and to reduce HF rehospitalizations has been demonstrated in several trials (27-29). In a recent Cochrane review, both non-invasive RM and structured telephone support have been shown to offer statistically and clinically meaningful benefits to patients with HF by reducing all-cause mortality (30). A meta-analysis of five trials evaluating the impact of hemodynamic-guided HF management in patients with symptomatic HF showed about 38% reduction in the risk for HF-hospitalizations (31). Table 1 summarizes the key studies conducted in the field of RM.

The Heart Failure Virtual Consultation (HFVC) is an internet-based video conference system that enables general practitioners, cardiologist and HF-nurses to meet virtually. HFVC proved to be a powerful tool for the delivery of specialist care and the democratization of knowledge in the community (32).

The authors of the Trans-European Network-Home-Care Management System (TEN-HMS) trial investigated whether home telemonitoring (HTM) improves outcomes compared to nurse telephone support (NTS) and usual care for patients with HF who are at high risk of
hospitalization or death. Patients were randomly assigned to HTM, NTS, or usual care in a 2:2:1 ratio. The primary end point was days lost as a result of death or hospitalization with NTS versus HTM at 240 days. There was no statistically significant difference between the two groups. The number of admissions and mortality were similar among patients randomly assigned to NTS or HTM, but the mean duration of admissions was reduced by 6 days with HTM. Patients randomly assigned to receive usual care had higher one-year mortality (45%) than patients assigned to receive NTS (27%) or HTM (29%) (p = 0.032) (33).

In a sub-analysis of the TEN-HMS, the investigators tested the possibility of predicting hospitalization due to worsening heart failure (WHF) using daily weight measurement. They concluded that many episodes of WHF are not necessarily associated with weight gain and therefore RM of weight alone may not have great value for HF-management (34).

Remote Management of Heart Failure Using Implantable Electronic Devices (REM-HF) is the largest prospective and randomized clinical trial conducted on RM with implanted devices. In this trial, 1,650 patients with HF who had an implanted cardiac device were randomized to active weekly review of RM data or usual care across nine UK hospitals, with an average follow-up of 2.8 years. The primary outcome of death or hospitalization from cardiovascular causes was the same in the RM group (42.4%) and the control group (40.8%) of patients (p=0.87), despite considerable extra activity being triggered by the remotely collected data (35).

The Influence of Home Monitoring on the Clinical Management of HF Patients with Impaired Left Ventricular Function (IN-TIME) study was a prospective randomized trial that analyzed the benefit in clinical outcomes of RM of implanted devices. In this study, 716 patients were recruited, and 664 patients were finally randomized to multiparameter RM in addition to standard of care or standard of care alone. The primary end point was a composite clinical score. This included all-cause death, HF hospitalization, change in New York Heart
Association (NYHA) class, and change in patient global self-assessment. The composite clinical score was better in the RM population. Improvement in composite outcome mainly resulted from a lower death rate in the RM group (estimated 1-year mortality 2.7% versus 6.8% (HR 0.37; 95% CI [0.16–0.83], p=0.012) (36).

While there is no clear explanation for the difference in the results between REM-HF and IN-TIME, the results could be attributed to the weekly RM in REM-HF compared with the daily review and intervention in IN-TIME.

The effectiveness of RM after discharge of hospitalized patients with HF was investigated in the *Better Effectiveness After Transition–Heart Failure* (BEAT-HF) trial, a clinical randomized trial conducted in 6 centers in California, USA. The follow-up period was in average 180 days. Centralized registered nurses conducted RM reviews, protocolized actions, and telephone calls. The primary outcome was readmission for any cause within 180 days after discharge. Secondary outcomes were all-cause readmission within 30 days, all-cause mortality at 30 and 180 days, and QoL at 30 and 180 days. At the end there was no reduction in 180-day readmissions among patients hospitalized for HF, in whom combined health coaching telephone calls and RM were performed (37). Patients’ adherence was a major limitation in this trial, given that only about 60% of patients were adherent for more than half of the time in the first 30 days.

*The Telemedical Interventional Management in Heart Failure II* (TIM-HF-2) a randomized, controlled, multicenter trial, has shown promising results. Eligible patients with HF were randomized (1:1) to either RM + usual care or to usual care only. Patients were followed for 12 months. The primary outcome was the percentage of days lost due to unplanned cardiovascular hospitalizations or all-cause death per 100 person-year. The main secondary outcomes were all-cause and cardiovascular mortality. The investigators found that patients assigned to RM had fewer lost days compared with patients assigned to usual care. Cardiovascular mortality was not significantly different between the two groups (27).
The sub-study of TIM-HF-2 investigated whether the biomarkers mid-regional pro-adrenomedullin (MR-proADM) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) could be used to identify low-risk patients unlikely to benefit from RM, thereby allowing more efficient allocation of the intervention. Both biomarkers were strongly associated with events. The primary endpoint of lost days increased from 1.0% (1.4%) in the lowest to 17.3% (17.6%) in the highest quintile of NT-proBNP (MR-proADM). The authors showed that Biomarker guidance in the RM would have saved about 150 h effort/year per 100 patients of the eligible population (38).

The CHAMPION trial (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients) investigated the utility of wireless pulmonary artery hemodynamic monitoring in chronic HF in reducing HF-hospitalization (28). CardioMEMSTM is a small sensor placed in the pulmonary artery. Readings can be taken (usually once daily) of the pulmonary artery pressure basis. Patients were randomly assigned to management with a wireless implantable hemodynamic monitoring system (treatment group) or to a control group for at least 6 months. The investigators of the trial showed a reduction in hospitalization for patients who were managed with a wireless implantable hemodynamic monitoring system. Information about pulmonary arterial pressure in addition to clinical signs and symptoms resulted in improved HF management (29, 39). The implantation of a wireless HF-monitoring system (CardioMEMSTM) in a real-world setting in patients with HF and NYHA class III symptoms has resulted in 80.4% reduction in HF- admissions and 69% reduction in all-cause admissions (28). The Hemodynamic Guided Management of Heart Failure (GUIDE-HF) clinical trial is currently recruiting (NCT03387813). The aim of this trial is to test the effectiveness of the CardioMEMSTM HF System in HF patients for whom there has been so far no indication for the use of this system, but who are at risk for future HF events or mortality (e.g., NYHA II).
There are few published data on RM with CardioMEMSTM for patients with left ventricular assist devices (LVAD). In a retrospective analysis of 436 patients who had received a CardioMEMSTM device, 108 of whom also received an LVAD (40), the mean pulmonary artery (PA) pressure at the time of CardioMEMSTM implantation was higher (p<0.001) in the group that subsequently received an LVAD. Mean PA pressures decreased after LVAD-implantation and remained stable for 1 year. The authors concluded that monitoring PA-pressure may help decide the timing of LVAD-implantation and in the monitoring of these patients.

In one meta-analysis, Zhe et al conducted a meta-analysis on 29 randomized clinical trials that included 10,981 patients followed for up to 36 months. In this analysis, telemonitoring (TM) included structured telephone support and interactive voice-response monitoring. TM was associated with fewer hospitalizations, all-cause (OR 0.82, 95% CI 0.73-0.91, p=0.0004) and cardiac (OR 0.83, 95% CI 0.72-0.95, p=0.007), and a lower all-cause mortality (OR 0.75, 95% CI 0.62-0.90, p=0.003) with a similar effect on HF-related mortality (OR 0.84, 95% CI 0.61-1.16, p=0.28) compared to the conventional healthcare (41).

**NOVEL AND UPCOMING DEVICES AND TECHNOLOGIES**

We will summarize here the most recent and upcoming technologies as well as the evidence supporting RM in patients with HF (Table 2).

**I. IMPLANTABLE ELECTRONIC DEVICES**

One of the longest established methods of RM is using the implantable cardiac devices to measure cardiopulmonary variables such as thoracic impedance (surrogate of lung fluid content), heart rate and heart rate variability (42, 43). Ongoing efforts and novel technologies
seek to improve detection algorithms of implanted devices and expand upon the success of the CardioMEMSTM implantable cardiopulmonary monitoring device.

**HeartLogic™ ALGORITHM**

The HeartLogic algorithm was developed using data from the MultiSENSE study (*Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients*). The following sensor measurements were incorporated: heart sounds (S1, S3), lung impedance, respiratory rate and volume, activity and night-time heart rate. The changes in sensors were weighted and aggregated based on a risk determination, resulting in a single composite index to alert clinicians when a patient’s HF is worsening.

HeartLogic was found to augment baseline NT-proBNP assessment. Furthermore, a retrospective analysis indicated that the HeartLogic algorithm might be useful to detect gradual worsening of HF and to stratify risk of HF decompensation (44, 45). Two studies seek to provide further evidence for clinical benefit:

- **Multiple Cardiac Sensors for the Management of Heart Failure** (MANAGE-HF) is a multicenter, global, prospective, open label, multi-phase trial intended to evaluate the clinical efficacy of the HeartLogic HF diagnostic feature. This trial is currently enrolling (NCT03237858).

  Phase II of the MANAGE-HF trial will assess the clinical effectiveness of RM of HF- patients with implanted CRT-D or ICD that contain the HeartLogic feature against patients with RM but without HeartLogic alerts.

- **PREEMPT-HF-trial** (*Precision Event Monitoring for Patients with Heart Failure using HeartLogic*) is currently enrolling (NCT03579641). There are no primary safety and/or efficacy endpoints for this study. Subjects will be followed for about 12 months after baseline
to observe the occurrence of clinical events. These are defined as following: hospitalization (any cause), hospitalization due to HF, HF-readmission 30-days after discharge, and HF-outpatient visit where unscheduled intravenous diuretics are prescribed in a setting that does not involve patient admission (emergency department, outpatient clinic) (Table 2).

HEART FAILURE RISK STATUS (HFRS) GENERATED BY CARDIAC IMPLANTABLE ELECTRONIC DEVICE (TRIAGE-HF)

HF-risk status (HFRS) generated by cardiac implanted electronic devices was investigated in 100 patients with HF in three Canadian Centers for up to 8 weeks (TRIAGE-HF) (NCT 01798797). Measurements included impedance/OptiVol (Medtronic Plc., MN, USA), patient activity, night heart rate, heart rate variability, percent CRT pacing, atrial tachycardia/atrial fibrillation, and episodes of untreated and device-treated arrhythmia. Patients with a high HFRS score were contacted by telephone to assess symptoms, and compliance with prescribed therapies, nutrition, and exercise. Clinician-assessed and HFRS-calculated risk were compared at study baseline and exit. Twenty-four high HFRS episodes were observed. Measurements associated with an increased risk of HF hospitalization included OptiVol index (n = 20), followed by low patient activity (n = 18) and elevated night heart rate (n = 12). High HFRS was associated with symptoms of worsening HF in 63% of cases (n = 15) increasing to 83% of cases (n = 20) when non-compliance with pharmacological therapies and lifestyle was considered. The authors concluded that HFRS might be a useful tool for RM of HF (46).
IMPLANTABLE PULMONARY ARTERY PRESSURE - MEASUREMENT (CORDELLA™)

In addition to the previously described CardioMEMS™, still the only FDA-approved pressure measurement device, other modalities are being currently tested. The Cordella™ system provides a comprehensive health status of the patient at home. The gathered data can be then shared with healthcare providers for further evaluation and management. The Cordella Sensor integrates PA-pressure data into the Cordella System to proactively deliver the information necessary to improve patient care between office visits.

The SIRONA trial ("Evaluating the Safety and Efficacy of the Cordella™ Heart Failure System NYHA Class III HF Patients") (NCT03375710) is a prospective, multi-center, open-label, single-arm clinical trial. Cordella™ is a pulmonary artery pressure sensor. The primary safety endpoint was freedom from adverse events associated with the use of Cordella™ HF system through 30 days post-implant. The primary efficacy endpoint was the accuracy of Cordella™ Sensor PA pressure measurements relative to standard-of-care fluid-filled catheter pressure measurements obtained by standard right heart catheterization (RHC) at 90 days post-sensor implant. The primary results of the first-in-human SIRONA-study are promising (47). A further Prospective, Multi-Center, Randomized, Controlled, Single Blind Clinical Trial Evaluating the Safety and Efficacy of the Cordella™ Pulmonary Artery Sensor System in New York Heart Association (NYHA) Class III Heart Failure Patients (PROACTIVE-HF Trial) has just started recruiting. The study is expected to be completed in May 2024 (NCT04089059).

LEFT ATRIAL HEMODYNAMIC MONITORING SYSTEM

An alternative to pulmonary arterial pressure monitoring is left atrial pressure monitoring (48). The ongoing Left Atrium Monitoring systEm for Patients With Chronic systOlic & Diastolic Congestive heaRt Failure trial (VECTOR-HF, NCT03775161) studies the safety
and reliability of the V-LAPT™ device in patients with HF irrespective of LVEF. V-LAPT™ is a wireless, battery-free microcomputer, placed directly on the inter-atrial septum. The first device has been implanted in February 2019. Altogether 30 patients are planned to be included in 6 European centers across Germany, Israel, Italy and England. The trial is estimated to be completed in August 2021.

II. NON-INVASIVE-MONITORING

Non-invasive monitoring for HF spans cardiac and extra-cardiac variables in an attempt to detect signs of cardiac decompensation.

LUNG FLUID VOLUME AND LUNG IMPEDANCE MEASUREMENT

Some studies have focused on non-invasive lung impedance-guided treatment in patients with HF (Impedance HF-trial) and showed reduced mortality and reduced hospitalization rates due to acute HF (AHF) (49). In addition, the extent of change in pulmonary fluid content using lung- impedance based therapy during HF-hospitalization has been shown to be strongly predictive of HF-readmission and event-free survival (50).

Remote Dielectric Sensing (ReDS™) is one example of a non-invasive technology used in the field of RM that contains clinical algorithms and performs an absolute measurement of lung fluid volume by using a focused electromagnetic RADAR beam through the right lung. Normal lung measures 20-35% lung fluid content (default target range). The measurement can be done without any skin contact in up to 45 seconds. Uriel et al. showed using ReDS™ strong correlations both in tissue- measured fluid content and to hemodynamic measurements with the pulmonary artery wedge pressure (PAWP) (51). In this study, receiver operating characteristic analysis of the ability to identify a PAWP ≥18 mm Hg resulted in a ReDS cutoff value of 34%, with an area under the curve of 0.85, a sensitivity of 90.7%, and a specificity of 77.1%. Overall, ReDS <34% carries a high negative predictive value of 94.9%.
In the Evaluation Study of Remote Dielectric Sensing (ReDS) Technology-Guided Therapy for Decreasing Heart Failure Re-Hospitalizations, the investigators concluded that ReDS-guided management has the potential to reduce HF readmissions in AHF patients recently discharged from the hospital (25). The results of SMILE-HF trial were presented at the HFSA 2019 (52). The study recruited 268 patients from 43 centers across the United States. The pre-specified endpoint of per-protocol changes in HF readmission were reduced in the ReDS™ treatment guided HF management arm (HR 0.52, 95% CI [0.31-0.87], P=0.01), which equates to a 48% readmissions reduction.

NON-INVASIVE INTRACARDIAC PRESSURE MONITORING (ICPM)

A novel method of intracardiac pressure monitoring uses a non-invasive portable ultrasound-based measurement system. The new system is based on the image time series processing estimating the changes of the oscillating traceable regions via the introduction of the new ultrasound generalized M-Mode and the notion of the derived image. The non-invasive system requires an initial calibration with simultaneous invasive pressure measurements, yet efforts are underway to eliminate this step using machine learning technology. The system has been successfully tested in animals (sheep) (53). Human validation trials were performed on 32 patients and a multicenter multinational study is pending. The intended in-home use will require the self-use of a portable ultrasound system by patients.

III. HF-DIAGNOSTICS USING WEARABLE DEVICES AND TECHNOLOGIES

There is currently a heightened focus on wearable monitoring technology both for detecting atrial fibrillation or for preventing hospitalization due to decompensated HF by observing early changes occurring before overt AHF takes place (54, 55).
Wearable health devices are part of digital and mobile health and represent potential instruments to improve HF-care and outcomes. DeVore et al described this topic nicely in a recently published review article (56). Available data are currently limited to observational studies or small clinical randomized trials. Wearables are being integrated into HF-trials as an intervention to assess outcomes. This may include lifestyle, pharmacological, device and mHealth interventions (57). Future wearables of HF can be applied externally and include skin patches, watches and contact lenses and may monitor lactate or electrolytes (58).

The Nanowear Wearable Heart Failure Management System Multiple Sensor Algorithm Development and Validation Trial is a multi-center prospective, non-randomized, observational study (NCT03719079). The aim is to enroll up to 500 subjects in order to collect data which includes at least 150 HF-hospitalizations in participating subjects. The trial is expected to be completed in December 2020. The study device is the Wearable Congestive Heart Failure Management System (WCHFS, also known as SimpleSENSE).

The observational multi-center study titled “Evaluating Mobile Health Tool Use for Capturing Patient-Centered Outcomes Measures in HF Patients” (NCT04191356) will evaluate the feasibility of a novel mobile health monitoring platform. Enrollment will start in 2020: 170 patients with HF are planned to be enrolled, and for 8 weeks the platform will capture patient-centered outcomes measures. The primary outcome is the correlation between physiology and accelerometer data collected from Everion and Apple Watch (i.e.: heart rate, single lead ECG report) with 6-minute walk test (6MWT), laboratory (i.e.: eGFR, troponin, creatinine, NT-proBNP) results, and QoL measured using Kansas City Cardiomyopathy Questionnaire KCCQ-12 & the- 5-level and 5-dimensions European quality of life (EQ-5D-5L) -questionnaire.
These small feasibility studies may improve understanding of the technology but do not address the core issue of whether what can be done should be done. Only randomized controlled trials will help determine the clinical and financial effectiveness of RM.

More studies and evidence are required before a routine integration of these new technologies in the daily routine work-up or screening of patients with HF would become feasible. The future will show if wearable technologies will prove themselves to be an effective means in the field of RM and the management of patients with HF. How wearable technologies can complement implanted technology and in what instances they can replace the more invasive technology have yet to be determined (59).

Several questions remain open, however, and need to be answered: Which patients should be monitored? It seems to be reasonable to apply the RM primarily to symptomatic patients (NYHA III-IV), who—suffer from cardiac decompensation in spite of GDMT. The best time frame to start RM would be pre-discharge or shortly after that (31). The chance of these patients to decompensate again is much higher than those with stable HF and the heightened risk might justify the costs resulting from applying RM in this group of patients. In addition, the method of RM is still to be chosen. For example, devices with multiple sensors might be superior to single sensor-method. Further issues should address the responsibility for reviewing the transmitted data and the frequency of the transmission and review of these data. Data should be transmitted securely to a medical center. It is expected that medical personnel will receive a large volume of data that needs to be processed and analyzed. Approving and paying for the additional costs resulting from RM is still an open question. An analysis based on the CHAMPION trial suggested that monitoring using the CardioMEMSTM device was cost-effective from a US-payer perspective, with the incremental cost to deliver one additional quality-adjusted life-year of approximately $30,000 in the USA (60). Unanswered questions in the field of RM are summarized in Figure 2.
clinical investigations will help to confirm and extend the existing evidence presented above and help to answer some of the questions raised.

In conclusion, RM is a promising way to monitor and manage patients with HF (Figure 3/Central Figure). RM could be performed non-invasively, through wearable devices, or by using developed algorithms integrated in implanted cardiac devices or invasively through continuous measuring of the pulmonary artery pressure. RM has been shown to improve the management and outcomes in patients with HF, but results do not apply to all technologies in all settings. Upcoming devices and technologies are being currently evaluated. Early results are promising. Questions regarding patient selection, timing of initiation and duration, and the most appropriate RM technology for each patient remain open. Further larger, randomized studies are required to refine our current knowledge and optimize patient care.
Acknowledgement: None

Conflict of interest (COI):
TB: No COI; MF: Consults for AxonTherapies, Galvani, Daxor and Edwards LifeSciences; AJ: No COI; SvH has been a paid consultant for and/or received honoraria payments from Bayer, Boehringer Ingelheim, BRAHMS, Chugai, Grünenthal, Helsinn, Hexal, Novartis, Respica, Roche, Sorin, and Vifor. SvH owns shares in Actim. SvH reports research support from IMI and the German Center for Cardiovascular Research (DZHK); AL: No COI; AMKR: Consultancy: Endotronic and SoniVie. Research Funding: Wellcome Trust, Medical Research Council UK, Novartis, Medtronic, Abbott, Endotronic, SoniVie, Actelion. AMKR is supported by a Wellcome Trust Clinical Research Career Development Fellowship (206632/Z/17/Z); KS is employee and shareholder in Boston Scientific; JGFC: research grants from Medtronic; share options from HeartFelt Technologies; research collaboration with Sensible Medical; equipment loan from Mespere; personal honoraria from Medtronic and Servier; WTA has received consulting fees from Abbott, Sensible Medical, and Vectorious; HS: Study honoraria to institution, travel expenses, consulting fees \(^1< 25,000\) €: 4tech Cardio, Abbott, Ablative Solutions, Ancora Heart, Append Medical, Axon, Bavaria Medizin Technologie GmbH, Bioventrix, Boston Scientific, Carag, Cardiac Dimensions, Cardiac Success, Cardimed, Celonova, Comed B.V., Contego, CVRx, Dinova, Edwards, Endologix, Endomatic, Emoteq, Hangzhou Nuomao Medtech, Holistick Medical, K2, Lifetech, Maquet Getinge Group, Medtronic, Mokita, Occlutech, Recor, Renal Guard, Terumo, Tritol, Vascular Dynamics, Vectorious Medtech, Venus, Venock, Vivesure Medical.; SDA reports grants and personal fees from Vifor Int, personal fees from Bayer, personal fees from Boehringer Ingelheim, personal fees from Novartis, personal fees from Servier, grants and personal fees from Abbott Vascular, personal fees from Impulse Dynamics, personal fees from Cardiac Dimensions, outside the submitted work.

\(^1\) Relationships with industry are limited to reimbursement for clinical trials. Personal honoraria had not been paid.
REFERENCES


10. Ryan AM, Nallamothu BK, Dimick JB. Medicare's public reporting initiative on hospital quality had modest or no impact on mortality from three key conditions. *Health Aff (Millwood)*. 2012 Mar;31(3):585-592.


FIGURE LEGENDS

**Figure 1:** This diagram shows the phases of decompensated HF. Currently, we tend to act when patients are in phase C. Ideally, we should react earlier when patients are still in phase A or B. RM offers different possibilities in this regard [modified from Adamson et al. Curr Heart Fail Rep, 2009. 6(4): p. 287-92].

**Figure 2:** This diagram represents the still-open questions in the field of RM.

**Figure 3:** This diagram represents the different RM options (wearables, non-invasive devices like ReDS™, integrated algorithms in implanted cardiac devices like HeartLogic™). The resulting data will be transferred to medical centers and will be reviewed frequently from medical personnel (physicians, trained nurses, etc.). Accordingly, decisions should be made to modify the medical therapy or to organize an emergent admission of the patients. Alternatively, no action could be required assuring a stable condition of HF patients.
Table 1: Overview of important trials in RM in patients with HF

<table>
<thead>
<tr>
<th>Trial</th>
<th>Number of patients</th>
<th>Years conducted</th>
<th>Follow-up</th>
<th>Patients selection</th>
<th>Method of RM</th>
<th>Measured parameters</th>
<th>Primary endpoint</th>
<th>Primary endpoint met</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEN-HMS</td>
<td>29</td>
<td>Published 2005</td>
<td>240 days</td>
<td>-Recent admission of HF. -LVEF&lt;40%</td>
<td>Home Telemonitoring</td>
<td>weight, blood pressure, heart rate and rhythm with automated devices linked to a cardiology center</td>
<td>days lost as a result of death or hospitalization with NTS versus HTM at 240 days.</td>
<td>+/-</td>
</tr>
<tr>
<td>BEAT-HF</td>
<td>28</td>
<td>2011-2013</td>
<td>180 days</td>
<td>-Currently HF-hospitalization - adults &gt;50 years old</td>
<td>health coaching telephone calls and telemonitoring</td>
<td>daily blood pressure, heart rate, symptoms, and weight</td>
<td>readmission rate for any cause within 180 days after discharge.</td>
<td>-</td>
</tr>
<tr>
<td>TIM-HF2</td>
<td>33</td>
<td>2013-2017</td>
<td>12 months</td>
<td>-LVEF &lt;45% or LVEF &gt;45% and 1 diuretic in the permanent medical therapy. -NYHA II-III</td>
<td>Remote patient monitoring</td>
<td>Daily bodyweight, systolic and diastolic blood pressure, heart rate, analysis of the heart rhythm, peripheral capillary oxygen saturation and a self-rated health status</td>
<td>the percentage of days lost due to unplanned cardiovascular hospitalizations or all-cause death per 100 person-year.</td>
<td>+</td>
</tr>
<tr>
<td>CHAMPION</td>
<td>34</td>
<td>2007-2009</td>
<td>6 months</td>
<td>NYHA III</td>
<td>Wireless implanted MEMS-based PA pressure sensor</td>
<td>PA-Pressure</td>
<td>-Rate of HF- Related Hospitalizations -Freedom from a Device/System-related Complication. -Freedom from Pressure Sensor Failure.</td>
<td>+</td>
</tr>
<tr>
<td>REM-HF</td>
<td>1650</td>
<td>2011-2014</td>
<td>2.8 years</td>
<td>NYHA II-IV and implanted</td>
<td>weekly data downloads from patients’ devices</td>
<td>ICD, CRTD/P. Devices were used from multiple manufacturers</td>
<td>death or hospitalization from cardiovascular causes.</td>
<td>-</td>
</tr>
</tbody>
</table>
Table 1: Overview of important trials in RM in patients with HF

| Cardiac device (ICD, CRTD/P) | with simultaneous review by remote monitors | (Medtronic, Boston scientific, St. Jude medical): 
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Bi-ventricular pacing %, Nocturnal HR, Thoracic Impedance only in Medtronic and some St. Jude medical devices, Activity levels, AT/AF burden, Ventricular arrhythmias, Therapy from device, Heart rate variability, Lead integrity, Device programming, V–V interval at time of D/L.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**IN-TIME**

| 40 | 716 | 2007-2013 | 12 months | -NYHA II-III -LVEF <35% and implanted cardiac devices (ICD, CRTD/P) | Automatic, daily, implant-based, multiparameter telemonitoring (onset of arrhythmias, duration of daily physical activities, ventricular ectopy, heart rate variability, mean heart rate in 24 h, mean heart rate at rest). | ICD, CRTD/P. (BIOTRONIK GmBH, Germany) | A composite clinical score consisting of all-cause death, HF hospitalization, change in NYHA class, and change in patient global self-assessment. |

CRTD/P: Cardiac resynchronization therapy Defibrillator/pacemaker, ICD: Implantable Cardioverter Defibrillator, HF: heart failure, NYHA: New York Heart Association.
<table>
<thead>
<tr>
<th>Study Description</th>
<th>Number of patients</th>
<th>Recruitment status</th>
<th>Patients selection</th>
<th>Method</th>
<th>Primary outcomes measures</th>
</tr>
</thead>
<tbody>
<tr>
<td>SMILE-HF</td>
<td>268</td>
<td>Terminated 2017</td>
<td>Patients with current hospitalization for ADHF, regardless of the LVEF</td>
<td>ReDS</td>
<td>-The rate of recurrent events of HF readmissions.</td>
</tr>
<tr>
<td>MANAGE-HF</td>
<td>2700</td>
<td>Completion estimated in January 2025</td>
<td>Implanted ICD/CRTD - NYHA II-III</td>
<td>HeartLogic</td>
<td>-All-cause mortality. -HF- hospitalization.</td>
</tr>
<tr>
<td>PREEMPT-HF</td>
<td>3750</td>
<td>Study completion anticipated in January 2026</td>
<td>Documented HF -CRTD with HeartLogic -HF- hospitalization. -All-cause mortality. -HF- hospitalization.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRIAGE-HF</td>
<td>100</td>
<td>Completed 2013-2015</td>
<td>non-randomized, all subjects who have been implanted with an ICD or CRT-D for at least 3 months.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CardioMEMS HF System OUS post Market Study</td>
<td>800</td>
<td>Recruiting (2016-2023)</td>
<td>HF-patients with NYHA Class III who have experienced a HF-hospitalization within the past 12 months.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SIRONA-HF</td>
<td>15</td>
<td>Completion estimated in February 2021</td>
<td>NYHA Class III</td>
<td>Cordella™</td>
<td>-Safety Freedom form Adverse events. -Efficacy: Accuracy.</td>
</tr>
<tr>
<td>PROACTIVE-HF</td>
<td>900</td>
<td>Completion estimated in May 2024</td>
<td>NYHA Class III</td>
<td>Cordella™</td>
<td>-Mortality and HF Hospitalizations or Emergency Department/ Hospital Outpatient IV diuretic visits. -Safety: Device system related complication. -Safety: Pressure sensor failure.</td>
</tr>
<tr>
<td>VECTOR-HF</td>
<td>30</td>
<td>Completion estimated in August 2021</td>
<td>NYHA III, ambulatory IV</td>
<td>V-LAP™</td>
<td>-Safety: Device/system related complication. -Performance accuracy.</td>
</tr>
<tr>
<td>NANOSENSE</td>
<td>500</td>
<td>Completion estimated in December 2020</td>
<td>-At least 150 HF-patients. -The patient is either hospitalized with a primary diagnosis of acute or was discharged with a primary diagnosis of AHF within 2 weeks prior to enrollment -NYHA Class II-IV at time of enrollment.</td>
<td>SimpleSENSE</td>
<td>-To develop and validate a multi-parameter algorithm for the detection of HF prior to a HF event.</td>
</tr>
</tbody>
</table>

CRTD/P: Cardiac resynchronization therapy Defibrillator/pacemaker, ICD: Implantable Cardioverter Defibrillator, HF: heart failure, NYHA: New York Heart Association.
The beginning of cardiac decompensation!

- Stable compensated HF-patient
- Raised Intracardiac Diastolic Pressures (Sensor or Biomarker)
- Increased Tissue Water (Bio-impedance)
- Weight Gain
- Symptoms

0 days

Figure 1
Which patients should be monitored?

Why: should RM be done? How: Invasive or not?

Who will cover the additional costs?

How often should measurements be made?

When to do RM? At onset of HF? After episode of decompensation?

How long to do RM? High-risk periods? Life-long?

Who is responsible for reviewing results?

Patient Engagement

Telemedicine - Remote Monitoring (RM)
No action is required

Optimization of HF-Therapy

Further decisions taken by physician as necessary

Emergency admission

Figure 3

Wearable devices

Non-invasive monitoring, e.g. ReDS™

Integrated algorithms in implanted devices, e.g. HeartLogic™

Invasive monitoring, e.g. CardioMEMS™, Cordella™

Data processing and analysis. Protocol based decision making/optimization of HF-Therapy